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Abstract 
Understanding the intricate pathways modulating appetite and subsequent food intake 
is of particular importance considering the rise in obesity incidence across the globe. The 
serotonergic system, specifically the 5-HT2C receptor, has shown to be of critical importance in 
the regulation of appetite and satiety. The GHS-R1a receptor is another key receptor well-
known for its role in the homeostatic control of food intake and energy balance. We recently 
showed compelling evidence for an interaction between the GHS-R1a receptor and the 5-HT2C
receptor in an in vitro cell line system heterologously expressing both receptors. Here, we 
investigated this interaction further. First, we show that the GHS-R1a/5-HT2C dimer-induced 
attenuation of calcium signalling is not due to coupling to GαS, as no increase in cAMP signalling 
is observed. Next, flowcytometry fluorescence resonance energy transfer (fcFRET) is used to 
further demonstrate the direct interaction between the GHS-R1a receptor and 5-HT2C receptor. 
In addition, we demonstrate co-localized expression of the 5-HT2C and GHS-R1a receptor in 
cultured primary hypothalamic- and hippocampal rat neurons, supporting the biological 
relevance of a physiological interaction. Furthermore, we demonstrate that when 5-HT2C 
receptor signalling is blocked, ghrelin’s orexigenic effect is potentiated in vivo. In contrast, the 
specific 5-HT2C receptor agonist lorcaserin, recently approved for the treatment of obesity, 
attenuates ghrelin-induced food intake. This underscores the biological significance of our in 
vitro findings of 5-HT2C receptor-mediated attenuation of GHS-R1a receptor activity. Together, 
this study demonstrates, for the first time, that the GHS-R1a/5-HT2C receptor interaction 
translates into biological significant modulation of ghrelin’s orexigenic effect. This data 
highlights the potential development of a combined GHS-R1a and 5-HT2C receptor treatment 
strategy in weight management. 
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Introduction 
The gastric-derived-peptide ghrelin acts as the endogenous ligand for the growth 
hormone secretagogue (GHS-R1a) receptor, which is also known as the ghrelin receptor 1, 2. 
Ghrelin is the only known gut-peptide exerting an orexigenic effect via the activation of the 
centrally expressed GHS-R1a receptor 3-6 and has thus received much attention as an anti-
obesity drug target 7-16. However, despite previous and ongoing drug development efforts, no 
weight-loss drugs that target the ghrelin receptor are currently on the market. 
Initially, the GHS-R1a receptor was found to function as a homodimer 17, 18. However, 
recently, the GHS-R1a receptor has also been shown to heterodimerize with other GPCRs 
involved in appetite regulation and food reward (for review see 19), including its truncated 
splice variant, the GHS-R1b receptor 18, 20-22, the melanocortin 3 receptor (MC3) and the 
dopamine receptors (D1 and D2) 23-27. Moreover, our lab has demonstrated compelling evidence 
for a functional interaction between the GHS-R1a and the 5-HT2C receptor 27. 
Interestingly, serotonergic signaling has since long been known to be involved in 
controlling food intake and to impact on satiety 28-38. Individuals with normal regulated brain 
serotonin (5-hydroxytryptamine, 5-HT)  levels are more easily satiated and display a better 
control over carbohydrate cravings inhibiting sugar intake more readily 39, 40. Moreover, several 
drugs targeting the central serotonergic system, such as sibutramine and fenfluramine, have 
been specifically developed to induce satiety, or have been found to reduce food intake as a 
secondary effect, such as is the case for the 5-HT2B/2C agonist m-chlorophenylpiperazine (mCPP) 
29, 37, 41, 42. Unfortunately, none of these drugs have been without heart and pulmonary 
vasculature side-effects, or have been associated with a poor efficacy and other non-specific 
effects 33. 
The centrally expressed serotonin 2C (5-HT2C) receptor, in particular, has been shown to 
stimulate satiety via excitatory neurotransmission 29-34, 43. Indeed, a large amount of literature 
has validated the critical role played by the 5-HT2C receptor, which has substantiated this 
receptor as a viable target for the development of therapeutics in appetite control and weight 
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management 30-38. The recently approved 5-HT2C agonist lorcaserin is the first successful 5-HT2C 
receptor-targeting drug to reduce weight in the treatment of obesity 44-47. 
Interestingly, the expression of the central 5-HT2C receptor 48, 49 corresponds with the 
expression profile of the neuronal circuits expressing the GHS-R1a receptor 50-52, which is a first 
requirement for a physical interaction or dimerization. In addition, reciprocal interactions 
between the serotonin and ghrelin signalling pathways have been described previously. Indeed, 
administration of ghrelin to hypothalamic synaptosomes 53 was shown to inhibit 5-HT release, 
as was direct administration of ghrelin to hippocampal slices 54. Similarly, recent data has 
demonstrated an increased serotonergic turnover in the amygdala and altered serotonin 
receptor mRNA levels (including the 5-HT2C receptor) in the amygdala and dorsal raphe, 
following acute central ghrelin administration 55. Moreover, attenuated increases in acylated-
ghrelin were observed in response to an overnight fast in mice following pharmacological 
increases of brain serotonin levels or direct 5-HT2C receptor agonism 56. In addition, direct 
administration of serotonin or the 5-HT2 receptor agonist 5-dimethoxy-4-iodoamphetamine 
(DOI) attenuated ghrelin’s orexigenic effect in rats 57. We hypothesize that this serotonin-
mediated attenuation of ghrelin signalling is mediated via crosstalk of the GHS-R1a receptor 
with the 5-HT2C receptor, potentially in a direct physical interaction. In line with this hypothesis, 
we have previously shown a functional interaction between the GHS-R1a and 5-HT2C receptor in 
vitro 27, demonstrating an attenuated GHS-R1a signalling following co-expression of the 5-HT2C 
receptor, which reinforces the physiological relevance of the GHS-R1a/5-HT2C dimer. 
However, although evidence for dimerization in vitro is compelling, in general the 
existence of GPCR dimers in native tissue has been questioned because of the paucity of reports 
demonstrating an interaction in vivo. In this study, we further investigate the interaction 
between the GHS-R1a and 5-HT2C receptor in relation to its function in appetite and we analyse 
the significance of the interaction of these two key receptors in vivo. Specifically, the co-localized 
expression of endogenous levels of these receptors in neuronal cultures is investigated using a 
recently described fluorescein-labelled ghrelin peptide tracer 58, 59. Finally, the effects of specific 
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5-HT2C receptor antagonism versus agonism on ghrelin’s orexigenic effect is analysed in mice. 
To our knowledge this is the first study to show functional relevance of a specific GHS-R1a and 
5-HT2C receptor interaction on food intake behaviour in vivo. This data suggest the potential of
combined GHS-R1a receptor antagonism and 5-HT2C receptor agonism as a novel therapeutic 
strategy in weight management. 
Results and Discussion 
Fluorescence energy transfer upon co-expression of the GHS-R1a receptor with the 5-HT2C 
receptor 
Heterodimerization of the GHS-R1a receptor with two variants of the 5-HT2C receptor was 
investigated using flow cytometry fluorescence energy transfer (FRET). To this end, Hek293A 
cells stably expressing the unedited 5-HT2C receptor or a partially edited isoform, 5-HT2C-VSV-
eGFP, both c-terminally fused with an enhanced green fluorescent fusion protein (eGFP), were 
transduced with lentiviral vectors expressing the GHS-R1a receptor C-terminally fused with a 
red fluorescent tag (lvGHS-R1a-TagRFP). The 5-HT2C receptor is prone to post-transcriptional 
RNA editing, which is the enzymatic conversion of an adenosine to inosine residues on 5 specific 
nucleotide positions (A, B, C, D, E) in the 2nd intracellular loop and is thought to be associated 
with a reduced receptor functioning 60-66. Therefore, we included both the unedited 5-HT2C 
receptor and the partly edited 5-HT2C–VSV receptor, which is the most abundantly expressed 5-
HT2C receptor isoform in human brain. Indeed, the 5-HT2C–VSV receptor isoform is particularly 
abundant in the hypothalamus 65, 67, where an increased 5-HT2C receptor editing has been linked 
with changes in feeding behaviour and fat mass 38, 66, 68. Noteworthy increases in FRET levels, as 
percentage of tagRFP expression, were observed 72hrs post transduction (Figure 1). Following 
lentiviral transduction of Hek293 cells with the lvGHS-R1a-tagRFP vector, 61.6% of cells were 
analysed as positive for tagRFP expression (Figure 1, 1st row, column 2), with relatively no FRET 
signal (1.6%, Figure 1, 2nd row, column 2), which demonstrates successful lentiviral 
transduction. In addition, no tagRFP or FRET signal was observed in Hek293 wild type (Hek293 
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wt) cells or Hek293 cells stably expressing 5-HT2C-eGFP or the 5-HT2C-VSV variant (Figure 1, 1st 
and 2nd row). Hek cells stably expressing 5-HT2C-eGFP or the 5-HT2C-VSV variant showed an 
increase in tagRFP expression of respectively 38.7% and 61.5%, when transduced with the 
control-tagRFP vector (Figure 1, 3rd row, column 1 and 2). Similar percentages of 68.3% and 
52.2% were observed following transduction with the lvGHS-R1a-tagRFP vector in Hek 5-HT2C-
eGFP or the Hek 5-HT2C-VSV-eGFP cells, respectively (Figure 1, 3rd row, column 3 and 4). Finally, 
when analysing flow cytometry fluorescence energy transfer as a measure of 
heterodimerisation, co-expression of GHS-R1a-tagRFP in Hek293 5-HT2C-eGFP or Hek293 5-
HT2C-VSV-eGFP cells increased FRET signal from 1.2% to 12.8% and 1.9% to 30.26% compared 
to control-TagRFP vectors, respectively (Figure 1, 4th row). These significant increases in FRET 
signal are further evidence of a physical interaction between the GHS-R1a receptor and the 5-
HT2C receptor. Interestingly, we consistently found a >2x higher percentage of FRET signal when 
the GHS-R1a receptor is co-expressed with the edited 5-HT2C-VSV variant of the receptor 
compared to the fully unedited 5-HT2C receptor. This may suggest that 5-HT2C receptor editing 
can modulate dimer formation and warrants further investigations. 
Co-expression of the 5-HT2C receptor attenuates GHS-R1a-mediated intracellular calcium 
mobilization without altering cAMP signalling 
The GHS-R1a receptor as well as the 5-HT2C receptor couple to the Gq protein, which leads to 
Gq-subunit mediated increase in phospholipase C, which subsequently elevates intracellular 
calcium levels. To assess the functional consequences of an interaction of the GHS-R1a receptor 
with the 5-HT2C receptor we analysed ligand-mediated downstream signalling consequences 
following co-expression of fluorescently tagged receptors. To this end, heterologous cells co-
expressing the GHS-R1a-EGFP receptor and the 5-HT2C-RFP receptor were analysed for ligand-
mediated intracellular calcium increase as well as intracellular cAMP levels. The dose-
dependent ghrelin-mediated intracellular calcium influx in Hek293 cells stably expressing the 
GHS-R1a receptor, previously shown to be independent of fluorescent tag (Schellekens, van 
Oeffelen et al. 2013), was reduced when co-expressing the 5-HT2C receptor (Figure 2 A). In 
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addition, a similar attenuation of the GHS-R1a-mediated intracellular calcium mobilization upon 
co-expression of the 5-HT2C receptor was observed when the synthetic GHS-R1a ligand, 
MK0677, was used (Figure 2 B). This is in line with our previous study and confirms the 5-HT2C 
receptor-mediated attenuation of GHS-R1a receptor signalling, which concurs the interaction 
between the two receptors 27. Previously, it has been shown that the GHS-R1a receptor 
dimerizes with the dopamine D1 receptor leading to an enhanced dopamine induced c-AMP 
accumulation 24 and an attenuation of GHS-R1a-mediated calcium signalling 27. This may suggest 
a dimer-induced switch in GHS-R1a receptor G-protein coupling from Gαq to Gαs, which has 
been previously suggested for neuronal GHS-R1a receptors expressed in neuropeptide Y (NPY) 
cells of the arcuate nucleus of the hypothalamus 69. Thus, we set out to determine if the 
attenuated GHS-R1a receptor-mediated calcium mobilization observed here is due to a switch in 
G protein coupling from Gαq to Gαs. To this end, we measured cAMP increases in Hek293 cells 
expressing single receptors or co-expressing both the GHS-R1a and 5-HT2C receptors (Figure 3). 
First, we analysed Hek293 cells transduced with the D1 receptor expressing vectors (lvDRD1-
tagRFP) as a positive controls (Figure 3A and B), as the D1 receptor is coupled to the G protein 
Gαs, and receptor ligand binding subsequently activates adenylyl cyclase, leading to increasing 
intracellular concentrations of the second messenger cAMP. Indeed, a significant increase in 
intracellular cAMP was observed following exposure to the D1 agonist, 6,7-ADTN hydrobromide 
(0.5nM), in Hek293 cells transiently expressing the D1 receptor following lentiviral transduction 
but not in cells stably expressing the 5-HT2C receptor (Figure 3A) or the GHS-R1a receptor 
(Figure 3B). No cAMP responses were observed in Hek293 cells transiently expressing the D1 
receptor following serotonin (100nM) or ghrelin (100nM) exposure (Figure 3A and B). In 
addition, no ligand-mediated cAMP responses were observed in Hek293 cells stably expressing 
the 5-HT2C-eGFP receptor (Figure 3A and 3C) or in 5-HT2C-expressing cells transduced with lv-
GHS-R1a-tagRFP vectors (Figure 3C). Moreover, no ligand-mediated cAMP response were 
observed in Hek-GHS-R1a-EGFP cells (Figure 3B and D) or in Hek-GHS-R1a-EGFP cells 
lentivirally transduced to express 5-HT2C-tagRFP receptor (Figure 3D). Similar results were 
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obtained in cells co-expressing the GHS-R1a receptor with the partially edited 5-HT2C-VSV 
isoform (data not shown). Thus, co-expression of the 5-HT2C receptor with the GHS-R1a 
receptor, following lentiviral transductions does not induce intracellular cAMP production and, 
hence, does not alter G protein coupling in Hek293 cells. 
Co-localization of the 5-HT2C receptor and fluorescein-ghrelin staining ex vivo 
Next, endogenous co-expression of the GHS-R1a receptor and the 5-HT2C receptor was 
investigated in rat neuronal cultures of the hypothalamus and hippocampus (Figure 4). The 
hypothalamus is the main brain region integrating peripheral metabolic information controlling 
the homeostatic regulation of appetite and food intake 70, 71. The hippocampus is a brain 
structure involved in learning and memory function and has recently been linked with food 
intake control 72. In addition, the 5-HT2C receptor is strongly expressed in the hippocampus and 
on pro-opiomelanocortin (POMC) expressing neurons in the arcuate nucleus of the 
hypothalamus as well as in other hypothalamic regions 48, 49, 73, 74. Moreover, a recent study by 
Bonn et al., demonstrates that the 5-HT2C receptor can also be found on NPY producing neurons 
75, 76, which was previously not recognized. In addition, a significant number of neurons in the 
hippocampus express the GHS-R1a receptor 51, 58, 77-79 as well as do most regions of the 
hypothalamus 50-52. Specifically, in the arcuate nucleus, the GHS-R1a receptor is strongly 
expressed on NPY neurons, with 94% of the NPY neurons demonstrating GHS-R1a mRNA, but 
also on the POMC neurons , albeit only in 8% of the POMC neurons 80. Here, we investigated the 
co-localization of endogenously expressed 5-HT2C receptor in primary cultured neurons of rat 
day 17 embryos (E17), using immunocytochemistry. Serotonergic neurons develop at E16 after 
which mucosal enterochromaffin cells containing the largest store of mammalian serotonin 
start to develop 81. Therefore, neurons were cultured from rat pups at E17 to ensure 5-HT2C 
receptor expression. Central expression of the GHS-R1a receptor was analysed using a variation 
of a recently described method using fluorescein-ghrelin 82, a novel strategy to detect specific 
GHS-R1a receptor expression 58. Co-localization of the 5-HT2C receptor and fluorescein-ghrelin 
binding was correlated in primary rat hypothalamic cells (Figure 4, upper panel) as well as 
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primary cultures of neurons from the hippocampus (Figure 4, bottom panel). Immunostaining 
of the 5-HT2C receptor (red) and fluorescein-ghrelin binding (green) was mainly observed in the 
cell bodies of both neuronal cultures. In the hypothalamus, positive cells were much less 
frequent but most of them co-expressed both receptors. In the hippocampus, both receptors 
were expressed at higher levels and cells expressing only one receptor were more frequently 
found. Indeed, the insert in the bottom picture shows two cells that are both positive for 
fluorescein-ghrelin binding to the GHS-R1a receptor but one of them lacking staining for the 5-
HT2C receptor (Figure 4, bottom panel). This data clearly demonstrates the co-localized 
endogenous expression of the GHS-R1a and 5-HT2C receptor, which is a first requirement for a 
physical interaction between these G-protein coupled receptors in vivo. 
Specific 5-HT2C receptor blockade potentiates ghrelin’s orexigenic effect in vivo 
Next, we analysed the effect of specific 5-HT2C receptor antagonism on ghrelin’s orexigenic 
potential in vivo. Food intake of male C57Bl/6 mice was analysed following intraperitoneal 
administration of the specific brain-penetrant 5-HT2C receptor antagonist SB242084, followed 
by a second intraperitoneal injection of ghrelin or vehicle (Figure 5). Repeated measures 
analysis revealed a significant mean effect of treatment compared to vehicle (F(3,28) = 6.535; p = 
0.002) and a significant interaction of time × treatment (F(6.1,46.932)=3.817; p = 0.003). Post 
hoc analysis of the cumulative food intake indicated that the significance of ghrelin’s orexigenic 
effect compared to vehicle tapers off after the 2 hr time point (Figure 5A). This is in line with 
previous findings from our lab and others demonstrating that a single administration of ghrelin 
causes an acute increase in food intake which is diminished over time 4, 83. Interestingly, the 
significance of the ghrelin-induced increase in food intake was maintained after the 2 hr time 
point following SB242084-mediated 5-HT2C receptor antagonism (p<0.01), resulting in a 
ghrelin-mediated increase in food intake which was still apparent at 9 hours, while the 5-HT2C 
antagonist has no effects on food intake when administered on its own (Figure 5A). We 
hypothesize that the 5-HT2C receptor interacts with the GHS-R1a receptor following its 
activation by ghrelin, potentially via a dynamic dimerization, and attenuates ghrelin’s orexigenic 
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effect, which is in line with our in vitro findings (Figure2 and see 27). Specific 5-HT2C receptor
antagonism maintains the significance of ghrelin’s orexigenic effect following acute 
administration. In addition, the interaction on food intake following ghrelin and SB242084 co-
administration, compared to ghrelin alone, are individually depicted in bar graphs and clearly 
visible at 8 and 24 hours after food placement, but not at 1hr (Figure 5B, C, D). At the 1 hr 
timepoint ghrelin’s effect is still significant compared to control and co-administration of the 5-
HT2C receptor antagonist here has no additional effect on food intake. Together, these data 
indicate that ghrelin-induced increases in food intake can be modulated via specific 5-HT2C 
antagonism, resulting in a longer duration of ghrelin’s orexigenic effect. 
Specific 5-HT2C receptor agonism attenuates ghrelin’s orexigenic effect in vivo 
Finally, we analysed the effect of specific 5-HT2C receptor agonism, using lorcaserin, on ghrelin’s 
orexigenic effect in vivo. To this end, cumulative food intake of male C57Bl/6 mice following 
subcutaneous administration of lorcaserin with and without intraperitoneal ghrelin was 
analysed (Figure 6). Repeated measures analysis revealed a significant mean effect of treatment 
compared to vehicle (F(3,29) = 3.308; p = 0.034) but no significant interaction of time × treatment 
(F(5.046, 48.775)=0.956; p = 0.454). Again an initial significant increase in food intake was 
observed following acute treatment with ghrelin compared to vehicle, which lasted up to 2 
hours, after which significance tapers off (Figure 6A, B, C, D). Interestingly, ghrelin’s initial 
orexigenic effect was not observed when animals also received the 5-HT2C specific agonist, 
lorcaserin, at 3mg/kg. Indeed, when the 5-HT2C receptor is activated using lorcaserin, the acute 
orexigenic effect is completely blocked in the first 2 hours. Furthermore, no effect on food intake 
was observed with this sub-threshold dose of lorcaserin on its own (Figure 6A). At the 8h 
timepoint ghrelin’s orexigenic effect compared to control is no longer observed, but the 
combination treatment actually has a significant decreased food intake compared to ghrelin, 
reinforcing the  significantly inhibition on ghrelin’s orexigenic effect by 5-HT2C receptor agonism 
(Figure 6D). 
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In summary, this study gives compelling in vitro and in vivo evidence, for a central interaction 
between GHS-R1a and 5-HT2C receptor signalling, in line with previous findings (Schellekens et 
al. 2013 JCB; Hansson et al. 2014 Neuropsychopharm). It is likely that this interaction occurs in 
the arcuate nucleus of the hypothalamus, but whether this interaction is via dimerization on 
POMC or NPY neurons, where both receptors are expressed, despite GHS-R1a receptor 
dominance on NPY and 5-HT2C receptor dominance on POMC neurons, remains to be 
determined. However, it is also possible that this interaction extends beyond the homeostatic 
hypothalamic regulation of food intake and may involve hedonic feeding behaviour. Indeed, 
recent studies have identified the ghrelinergic system as a key player in hedonic food intake 
behaviours, including the motivational drive to eat, the rewarding aspects of food intake and the 
stress-induced ingestion of palatable foods 84-92. Interestingly, the 5-HT2C receptor has also been 
implicated in reward-related behaviours 93, 94, which may explain some overlapping 
functionalities with the GHS-R1a receptor including involvement in the hedonic regulation of 
food intake. Another possibility to consider is that the interaction is not via a direct physical 
interaction but through an indirect mechanism mediated by the control both receptors have on 
the mesolimbic dopaminergic system, a key pathway for non-homeostatic feeding 95. It has 
previously been shown that 5-HT2C receptor agonism has an inhibitory control on dopaminergic 
neurons in the ventral tegmental area (VTA) through the activation of GABAergic interneurons 
(for review, see 96). In addition, the GHS-R1a receptor is expressed on dopaminergic neurons in 
the VTA, enabling ghrelin to have a direct stimulatory effect on the mesolimbic dopaminergic 
system 97. Indeed, detailed investigations into the potential interaction between GHS-R1a and 5-
HT2C receptor signalling through the mesolimbic pathway are now warranted. 
Conclusion 
Together, this study shows compelling evidence for a functionally relevant interaction 
between the GHS-R1a and 5-HT2C receptor. Pharmacological blockade of the 5-HT2C receptor 
enhances the duration of ghrelin-mediated increase in food intake in mice (Figure 5), which is in 
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line with the attenuation of ghrelin-mediated activation of the GHS-R1a in vitro when the 5-HT2C 
receptor is co-expressed (Figure 2). In addition, agonism of the 5-HT2C receptor, blocks ghrelin’s 
orexigenic effect in mice (Figure 6), which may partly explain the satiety inducing effects of 
therapeutic doses of the 5-HT2C receptor specific agonist, lorcaserin. This data uncovers a novel 
mechanism for fine-tuning GHS-R1a receptor-mediated food intake via serotonergic activity. 
These findings have important implications for the development of future pharmacological 
strategies in weight reduction. A more efficacious weight loss could potentially be achieved 
following the combined pharmacotherapeutic targeting of the ghrelinergic appetite signalling 
pathway and the 5-HT2C receptor-mediated induction of satiety, thereby enhancing specificity 
and reducing side effects. Indeed, a combined pharmacological treatment to target both the 
GHS-R1a and 5-HT2C receptor simultaneously might be a novel therapeutic approach in the 
treatment of eating disorders and obesity, and future investigations are warranted. In addition, 
a potential interaction of the GHS-R1a receptor and the 5-HT2C receptor in reward centers 
regulating the hedonic aspects of food intake, including the VTA, is likely to broaden the 
application potential of novel ghrelinergic and serotonergic pharmacotherapeutics. 
Methods
Receptor ligands 
Ligands were prepared as previously described 27. Briefly, the endogenous ligand of the GHS-
R1a receptor, ghrelin (SP-GHRL-1; Innovagen), the non-peptide GHS-R1a receptor agonist, 
MK0677 (SP960334C; NeoMPS), 5–hydroxytryptamine (5-HT, H9523; Sigma), the D1 receptor 
agonist, 6,7-ADTN hydrobromide (Asc-150, Ascent Scientific), and the GHS-R1a specific inverse 
agonist, peptide [D-Arg1, D-Phe5,D-Trp7,9, Leu11]-substance P (SP-analog, #1946; Tocris) were 
prepared at a 1mM stock solution in assay buffer, consisting of 1x Hanks balanced salt solution 
(HBSS) supplemented with 20mM HEPES. Stock solutions were further diluted in assay buffer to 
the required concentration for the in vitro assays. MK-0677 (also known as ibutamoren, L-
163,191) is a highly specific and potent full agonist of the GHS-R1a receptor, which can activate 
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signalling pathways at doses ranging from 0.2 – 1.4 nM) and, in vivo, has been shown to potently 
induce growth hormone (GH) and cortisol release 17, 98. The brain penetrant 5-HT2C specific 
antagonist SB242084 (#2901; Tocris) was prepared in DMSO as 20 mg/ml stock solution. For 
the in vivo cumulative food intake experiments stocks of ghrelin and SB242084 were further 
diluted in saline. The 5-HT2C specific agonist, (+/-)-lorcaserin hydrochloride (FL32280; 
Carbosynth) was directly prepared in sterile saline. 
Cell Culture 
Human embryonic kidney cells (Hek293A) and were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Invitrogen) containing 4.5 g/L glucose and L-glutamine (Sigma Aldrich, 
Ireland), supplemented with 10% heat inactivated foetal bovine serum (FBS). Stably transfected 
Hek-GHS-R1a-EGFP, Hek-5-HT2C–EGFP and Hek-5-HT2C–VSV-EGFP cells were cultured in 
complete DMEM media supplemented with 300 ng/µl G418 as maintenance antibiotic, as 
previously described 27. All cells were maintained at 37°C and 5% CO2 in a humidified 
atmosphere to a confluence of >85% after which the cells were resuspended and propagated to 
a lower density. 
Transfection and lentiviral transduction 
Stably transfected Hek293A cell lines were generated following Lipofectamine LTX plus reagent 
(Invitrogen) mediated transfections with plasmids constructs expressing either the human GHS-
R1a receptor (Accession code: U60179.1), the unedited 5-HT2C-INI receptor (Genecopeia, 
H3309; Accession code: NM_000868) or the partly edited 5-HT2C-VSV receptor isoform 
(Genecopeia, T0336, Accession code: AF208053.1), as previously described 27, 99. In addition, 
Hek293A cells stably expressing the GHS-R1a-EGFP, the 5-HT2C-EGFP or the 5-HT2C-VSV-EGFP 
were transduced using lentiviral vectors to co-express the GHS-R1a, 5-HT2C, 5-HT2C-VSV or D1 
receptor constructs with a red fluorescent protein tag (RFP), as previously described 27. Cells 
were transduced with the GPCR-RFP expressing lentiviral vectors diluted in transduction media, 
consisting of DMEM with 2% heat-inactivated FBS, 1% NEAA and an additional 8μg/ml 
polybrene® (Sigma; H9268). Stable expression of the EGFP fluorescently-tagged GHS-R1a 
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receptors was routinely monitored using flow cytometry and expression levels were not 
affected by co-expression of the 5-HT2C-RFP construct following lentiviral transduction (data 
not shown). All cell lines were generated following approval and in full accordance with the 
Environmental Protection Agency (Ireland) under GMO register number G0331-01. 
Flow cytometry fluorescence resonance energy transfer (fcFRET) 
Cells were harvested 48 to 72 h after transduction using 37oC trypsin/EDTA, centrifuged and 
resuspended in PBS and passed through a cell strainer with 40 µm nylon mesh (BD Biosciences, 
#352340) prior to analysis. fcFRET analysis was performed on an LSR II cytometer (BD 
biosciences) and the eGFP was excited at 488 nm and detected with a 525/50 nm bandpass 
filter, while TagRFP was excited at 561nm and detected with a 610/20 nm bandpass filter. FRET 
between eGFP and TagRFP was measured by excitation at 488nm and detection with a 610/20 
nm bandpass filter (i.e. excitation of the “donor” but detection of the “acceptor”). For each 
sample, 104 cells were analysed. Live cells were gated according to forward and sideward 
scattering (FSC/SSC). Non transduced Hek293A cells were used for background correction. Cells 
expressing donor or acceptor construct only were used to compensate the signal in the FRET 
channel for spectral bleed-through and cross-excitation. Data was analysed using FACSDiva 
software (BD biosciences). 
Calcium mobilization assay 
Receptor-mediated changes in intracellular calcium (Ca2+) were analysed as previously 
described 27. Briefly, stably transfected cells were seeded in black 96-well microtiter plates at a 
density of 2.5 x 105 cells/ml (2.5 x 104 cells/well) and maintained for ~24hrs at 37°C in a 
humidified atmosphere containing 5% CO2. On the day of the assay, growth medium was 
aspirated off and cells were incubated with 25 µl of assay buffer (1x Hanks balanced salt 
solution, HBSS, supplemented with 20mM HEPES buffer) and 25 µl of Calcium 4 dye (R8141, 
Molecular Devices Corporation, Sunnyvale, CA) according to the manufacturer’s protocol. Cells 
were pre-treated with 1 µM of the GHS-R1a inverse agonist, peptide [D-Arg1,D-Phe5,D-
Trp7,9,Leu11]-substance P (#1946; Tocris), contained in the assay buffer, to inhibit constitutive 
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GHS-R1a receptor activity. Addition of agonist (25 µl/well) was performed by the Flexstation II 
multiplate fluorometer (Molecular Devices Corporation, Sunnyvale, CA), and fluorescent 
readings were taken for 80 seconds in flex mode with excitation wavelength of 485 nm and 
emission wavelength of 525 nm. The relative increase in cytosolic calcium [Ca2+] was calculated 
as the difference between maximum and baseline fluorescence (Vmax-Vmin; the treatment-
associated emission minus the unstimulated baseline emission) and depicted as percentage 
relative fluorescent units (RFU) compared to response as elicited by control, 3.3% fetal bovine 
serum (FBS). Values resulting from incorrect pipetting by the Flexstation were excluded from 
the analysis. Data was analysed using GraphPad Prism software (PRISM 5.0; GraphPAD 
Software Inc.). 
Cyclic adenosine monophosphate (cAMP) assay 
Intracellular 3’,5’-cyclic adenosine monophosphate (cAMP) was investigated 4 days after 
transduction of Hek-5-HT2C-INI-EGFP or Hek-5-HT2C-VSV with lentiviral constructs expressing 
RFP tagged D1 receptor (lvDR1-tagRFP) using the LANCE Ultra cAMP assay (PerkinElmer; 
#TRF0262), according to manufacturer’s instructions. Briefly, 5 µl of 2*105 cell/ml cell 
suspension was plated per well in a white 384-well plate (Perkin Elmer; Optiplate 6007291). 
Receptor activation was stimulated via the addition of 5 µl per well of the D1 receptor agonists 
6,7-ADTN hydrobromide (Ascent Scientific; Asc-150). Following 30 minute incubation at room 
temperature, 5 µl per well Eu-cAMP tracer in stimulation buffer and 5 µl per well monoclonal 
Ulight-anti-cAMP antibody, were added and incubated for an hour at room temperature, 
protected from light. Receptor mediated increases in cAMP competes with the Eu-cAMP tracer 
and subsequent decreases in time-resolved fluorescence resonance energy transfer (TR-FRET) 
emission was measured at 615 nm and 665 nm in the Synergy 2 Multi-Mode Microplate Reader 
(BioTek). A quench correction was performed minimizing false positives and false negatives by 
calculating the blank corrected ratio 665 nm/615 nm using the equation: F665,CS = [(F665,S – F 
665,BL) x F615,MAX]/F615,S. The blank value is separately measured by adding buffer to the 
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wells to obtain blank reading at 665 nm. Data was analysed using GraphPad Prism software 
(PRISM 5.0; GraphPAD Software Inc.). 
Embryonic primary neuronal cultures 
Hypothalamic and hippocampal primary neuronal cultures were established from brains of 
embryonic day 17 (E17) Sprague Dawley rats generated at the animal care facility of the 
IMBICE. All procedures were carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Research Council, USA. The 
protocol was approved by the Institutional Animal Care and Use Committee of the IMBICE. 
Briefly, pregnant rats were anesthetized and prepared to aseptically remove the embryos. Each 
brain was removed from the skull and placed on an ice-cooled petri dish with ventral side up. A 
micro-dissection forceps was used to pinch out the hypothalamic region posterior to the optic 
chiasm, anterior to the mammillary bodies, and 3 mm deep. With the dorsal side up, a sagittal 
cut was made down the midline of the brain separating the left and right hemisphere. The 
hippocampi were pinched out from each side of the brain following removal of the brainstem 
and white matter. All tissue was harvested in ice-cold Hank’s solution. Afterwards, cells were 
dissociated with a solution containing trypsin 0.25 mg/ml (cat#L2700-100, Microvet) and 
deoxyribonuclease I from bovine pancreas 0.28 mg/ml (cat# D5025, Sigma Aldrich) at 37 °C for 
20 min, then 300 μl of FBS was added to stop the digestion and cells were mechanically 
dissociated using several glass pipettes with consecutive smaller tip diameters. Cells were 
seeded on 24 x 24 mm glasses (5 x 104 cells/each) previously treated with poly-L-lysine (cat# 
P8920, Sigma Aldrich) and laid over 6-well plates. Cells were incubated at 37 °C in a 95 % O2 
and 5% CO2 atmosphere with DMEM/F12 1:1 medium supplemented with 10 % FBS, 0.25 % 
glucose, 2 mM glutamine (cat#21051-016, Gibco), 3.3 μg/ml insulin (Nordisk Pharm Ind, Inc, 
Clayton, North Carolina, United States), 5 U/ml penicillin G sodium salt (Richet, Buenos Aires, 
Argentina), 5 μg/ml streptomycin (Richet), 40 μg/ml gentamicin sulfate salt (Richet) and 1 % 
vitamin solution (cat#L2112-100, Microvet). On culture day 4, half of the incubation medium 
was replaced with medium containing cytosine β-D-arabinofuranoside (AraC) to reach a final 
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concentration of 5 μM (cat# C1768, SigmaAldrich). Neuronal cells were cultured for 7-10 days 
and then used to perform binding and immunocytochemistry assays. 
Fluorescein-ghrelin binding and serotonin receptor 2C immunostaining 
An in vitro binding assay was performed using fluorescein-ghrelin(1-18) 82 provided by Dr. 
Leonard Luyt from The University of Western Ontario, Canada. Specificity and accuracy of the 
fluorescein-ghrelin tracer as a strategy to visualize central GHS-R1a receptor expression has 
recently been demonstrated 58. The 5-HT2C receptor was detected with a mouse monoclonal 
antibody raised against the C-terminus of the receptor, previously validated for specificity in 
literature 100. Briefly, neuronal culture glasses were washed once with HBSS, covered with 400 
nM fluorescein-ghrelin in HBSS, incubated at room temperature for 20 min in a humidified 
chamber, and subsequently rinsed twice in HBSS. Cells were then fixed with 4% formaldehyde 
in phosphate buffered saline (PBS) pH 7.4 for 30 min at 4°C. In order to perform 
immunofluorescence staining, cells were treated with blocking solution (3% normal donkey 
serum and 0.25% TritonX in PBS) and then incubated with goat anti-fluorescein antibody 
conjugated to Alexa Fluor 488 (Molecular Probes, A-11096, 1:100 in blocking solution) for two 
days at 4°C and washed with PBS. Afterwards, cells were incubated with mouse anti-5-HT2C 
antibody (Santa Cruz, cat# sc-17797, 1:200 in blocking solution) for 24h at 4°C, washed with 
PBS, and finally incubated for 1h at room temperature with donkey anti-mouse antibody 
conjugated to Alexa Fluor 594 (Molecular Probes,  cat# A21203, 1:1000 in blocking solution) 
and rinsed with PBS. Negative controls were generated by omitting the primary or the 
secondary antibodies and no staining was found (data not shown). The slides were visualized 
within a week and stored at 4˚C. Fluorescent and phase contrast images were acquired with a 
Nikon Eclipse 50i microscope and a DS-Ri1 Nikon digital camera. The open-source image editing 
software FIJI was used to adjust contrast and brightness of microphotographs and to prepare 
the composite panels 101. 
Cumulative food intake 
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Male C57Bl/6 mice (Harlan, UK) were housed per four in standard holding cages at the animal 
care facility of University College Cork. The holding room temperature (21±1 °C) and humidity 
(55±10%) were controlled under a 12-h light/dark cycle (lights on 7.00 AM, lights off 7.00 PM). 
Water and food (2018S Teklad Global 18% Protein Rodent Diet) were available ad libitum 
throughout the study. The mice were habituated on three independent days to the experimental 
settings. Cumulative food intake studies were performed based on protocols described in 
previous studies (Asakawa, Inui et al. 2001; Finger, Schellekens et al. 2011). Briefly, the mice 
were weighed, single-housed in new cages in the experimental room and habituates for 20 
minutes before injections. To investigate the effect of 5-HT2C receptor antagonism on ghrelin’s 
orexigenic effect a cohort of 32 mice, n=8 per group, of approximately 11 week old animals were 
used. For the first injection, SB242084 (#2901; Tocris) (2.0 mg/kg in saline and 1.0% DMSO) 
and vehicle (saline with 1.0% DMSO) and for the second injection ghrelin (SP-GHRL-1; 
Innovagen) (200 nmol/kg in saline) and vehicle (saline) were administered via intraperitoneal 
(IP) administration (10 µl/gram of body weight). To investigate the effect of 5-HT2C receptor 
agonism on ghrelin’s orexigenic effect a cohort of 35 mice, n=7-10 per group, of approximately 
10 week old mice were used. First, the dose response effect (0, 1, 3 and 10 mg/kg) of a racemic 
mixture of the 5-HT2C receptor agonist, (+/-)-lorcaserin hydrochloride (FL32280; Carbosynth) 
on cumulative food intake was established following a 16 hr food restriction (data not shown). 
The sub-threshold dose of 3 mg/kg (0.3 mg/ml) was selected for further experiments as no 
effect on food intake was observed using this dose for up to 8 hours. For combination 
experiment, (+/-)-lorcaserin hydrochloride (FL32280; Carbosynth) (3.0 mg/kg in saline) and 
vehicle (saline) were administered subcutaneously (10 µl/gram of body weight) followed by a 
second injection ghrelin (Innovagen; SP-GHRL-1) (200 nmol/kg in saline) and vehicle (saline) 
via intraperitoneal (IP) administration (10 µl/gram of body weight). Time between the first and 
second injection was 15 minutes and pre-weighed chow food pellets were carefully placed in 
the experimental cages 20 minutes following the second IP injection. Thereafter, the amount of 
food was weighed at regular time intervals (20 min, 40 min, 1 h, 1h30min, 2 h, 3 h, 4 h, 5 h, 6 h, 7 
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h, 8 h, 9 h and 24 h). Animals that crumbled the pellet or wetted the pellet, which were both rare 
occasions, were excluded to ensure differences in weight reflect pellet consumed. At the end of 
the experiment the mice were placed back in their original cages in the holding room. 
Cumulative food intake was analysed using GraphPad Prism software (PRISM 5.0; GraphPAD 
Software Inc.). All experiments were conducted in accordance with the European Directive 
86/609/EEC, the Recommendation 2007/526/65/EC and approved by the Animal 
Experimentation Ethics Committee of University College Cork. 
Statistical analysis 
Statistical analyses were performed using SPSS software (IBM SPSS statistics 20, Chicago, IL, 
U.S.A.). For in vitro assays, significance was determined a two-way ANOVA at a significance level 
of p < 0.05. For food intake experiments, significant difference was determined with a general 
linear model repeated measurement combined with a one-way ANOVA with LSD post hoc test 
for each timepoint. If the data was non-spherical a Huynh-Feldt correction was applied. Graphs 
were expressed as mean ± SEM. Statistical significances were depicted as follows: * indicating 
p<0.05, ** indicating p<0.01 or *** indicating p<0.001. 
ACS Paragon Plus Environment
ACS Chemical Neuroscience
22 
References 
[1] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999) Ghrelin is a growth-
hormone-releasing acylated peptide from stomach, Nature 402, 656-660. 
[2] Davenport, A. P., Bonner, T. I., Foord, S. M., Harmar, A. J., Neubig, R. R., Pin, J. P., Spedding, M., Kojima,
M., and Kangawa, K. (2005) International Union of Pharmacology. LVI. Ghrelin receptor 
nomenclature, distribution, and function, Pharmacological reviews 57, 541-546. 
[3] Andrews, Z. B. (2011) Central mechanisms involved in the orexigenic actions of ghrelin, Peptides 32, 2248-
2255. 
[4] Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., and Matsukura, S. (2001) A
role for ghrelin in the central regulation of feeding, Nature 409, 194-198. 
[5] Tschop, M., Smiley, D. L., and Heiman, M. L. (2000) Ghrelin induces adiposity in rodents, Nature 407, 908-
913. 
[6] Kojima, M., Hosoda, H., and Kangawa, K. (2004) Clinical endocrinology and metabolism. Ghrelin, a novel
growth-hormone-releasing and appetite-stimulating peptide from stomach, Best practice & research 
18, 517-530. 
[7] Yi, C. X., Heppner, K., and Tschop, M. H. (2011) Ghrelin in eating disorders, Molecular and cellular
endocrinology 340, 29-34. 
[8] Patterson, M., Bloom, S. R., and Gardiner, J. V. (2011) Ghrelin and appetite control in humans--potential
application in the treatment of obesity, Peptides 32, 2290-2294. 
[9] Schellekens, H., Dinan, T. G., and Cryan, J. F. (2009) Lean mean fat reducing "ghrelin" machine:
hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity, Neuropharmacology 58, 2-
16. 
[10] Horvath, T. L., Castaneda, T., Tang-Christensen, M., Pagotto, U., and Tschop, M. H. (2003) Ghrelin as a
potential anti-obesity target, Curr Pharm Des 9, 1383-1395. 
[11] Zorrilla, E. P., Iwasaki, S., Moss, J. A., Chang, J., Otsuji, J., Inoue, K., Meijler, M. M., and Janda, K. D.
(2006) Vaccination against weight gain, Proceedings of the National Academy of Sciences of the 
United States of America 103, 13226-13231. 
[12] Soares, J. B., Roncon-Albuquerque, R., Jr., and Leite-Moreira, A. (2008) Ghrelin and ghrelin receptor
inhibitors: agents in the treatment of obesity, Expert opinion on therapeutic targets 12, 1177-1189. 
[13] Moulin, A., Ryan, J., Martinez, J., and Fehrentz, J. A. (2007) Recent developments in ghrelin receptor
ligands, ChemMedChem 2, 1242-1259. 
[14] Lu, S. C., Xu, J., Chinookoswong, N., Liu, S., Steavenson, S., Gegg, C., Brankow, D., Lindberg, R.,
Veniant, M., and Gu, W. (2009) An acyl-ghrelin-specific neutralizing antibody inhibits the acute 
ghrelin-mediated orexigenic effects in mice, Molecular pharmacology 75, 901-907. 
[15] Leite-Moreira, A. F., and Soares, J. B. (2007) Physiological, pathological and potential therapeutic roles of
ghrelin, Drug discovery today 12, 276-288. 
[16] Chollet, C., Meyer, K., and Beck-Sickinger, A. G. (2009) Ghrelin--a novel generation of anti-obesity drug:
design, pharmacomodulation and biological activity of ghrelin analogues, J Pept Sci 15, 711-730. 
[17] Holst, B., Brandt, E., Bach, A., Heding, A., and Schwartz, T. W. (2005) Nonpeptide and peptide growth
hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric 
modulators of ghrelin signaling, Molecular endocrinology (Baltimore, Md 19, 2400-2411. 
[18] Leung, P. K., Chow, K. B., Lau, P. N., Chu, K. M., Chan, C. B., Cheng, C. H., and Wise, H. (2007) The
truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin 
receptor, Cell Signal 19, 1011-1022. 
[19] Schellekens, H., Dinan, T. G., and Cryan, J. F. (2013) Taking Two to Tango: A Role for Ghrelin Receptor
Heterodimerization in Stress and Reward, Frontiers in Neuroscience 7. 
[20] Chan, C. B., and Cheng, C. H. (2004) Identification and functional characterization of two alternatively
spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream 
Acanthopagrus schlegeli, Molecular and cellular endocrinology 214, 81-95. 
[21] Chow, K. B., Sun, J., Chu, K. M., Tai Cheung, W., Cheng, C. H., and Wise, H. (2012) The truncated
ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms 
heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression, Mol Cell 
Endocrinol 348, 247-254. 
[22] Chu, K. M., Chow, K. B., Leung, P. K., Lau, P. N., Chan, C. B., Cheng, C. H., and Wise, H. (2007) Over-
expression of the truncated ghrelin receptor polypeptide attenuates the constitutive activation of 
phosphatidylinositol-specific phospholipase C by ghrelin receptors but has no effect on ghrelin-
stimulated extracellular signal-regulated kinase 1/2 activity, Int J Biochem Cell Biol 39, 752-764. 
ACS Paragon Plus Environment
ACS Chemical Neuroscience
23 
[23] Kern, A., Albarran-Zeckler, R., Walsh, H. E., and Smith, R. G. (2012) Apo-ghrelin receptor forms 
heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 
agonism, Neuron 73, 317-332. 
[24] Jiang, H., Betancourt, L., and Smith, R. G. (2006) Ghrelin amplifies dopamine signaling by cross talk
involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 
heterodimers, Mol Endocrinol 20, 1772-1785. 
[25] Rediger, A., Piechowski, C. L., Yi, C. X., Tarnow, P., Strotmann, R., Gruters, A., Krude, H., Schoneberg,
T., Tschop, M. H., Kleinau, G., and Biebermann, H. (2011) Mutually opposite signal modulation by 
hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors, The Journal of biological 
chemistry 286, 39623-39631. 
[26] Rediger, A., Tarnow, P., Bickenbach, A., Schaefer, M., Krude, H., Grüters, A., and Biebermann, H. (2009)
Heterodimerization of Hypothalamic G-Protein-Coupled Receptors Involved in Weight Regulation, 
Obesity Facts 2, 80-86. 
[27] Schellekens, H., van Oeffelen, W. E., Dinan, T. G., and Cryan, J. F. (2013) Promiscuous dimerization of
the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling, Journal 
of Biological Chemistry 288, 181-191. 
[28] Clifton, P. G., and Kennett, G. A. (2006) Monoamine receptors in the regulation of feeding behaviour and
energy balance, CNS Neurol Disord Drug Targets 5, 293-312. 
[29] Halford, J. C., Harrold, J. A., Boyland, E. J., Lawton, C. L., and Blundell, J. E. (2007) Serotonergic drugs :
effects on appetite expression and use for the treatment of obesity, Drugs 67, 27-55. 
[30] Lam, D. D., Przydzial, M. J., Ridley, S. H., Yeo, G. S., Rochford, J. J., O'Rahilly, S., and Heisler, L. K.
(2008) Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of 
melanocortin 4 receptors, Endocrinology 149, 1323-1328. 
[31] Dutton, A. C., and Barnes, N. M. (2006) Anti-obesity pharmacotherapy: Future perspectives utilising 5-
HT2C receptor agonists, Drug Discovery Today: Therapeutic Strategies 3, 577-583. 
[32] Garfield, A. S., and Heisler, L. K. (2009) Pharmacological targeting of the serotonergic system for the
treatment of obesity, Journal of Physiology 587, 49-60. 
[33] Miller, K. J. (2005) Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity, Molecular
Interventions 5, 282-291. 
[34] Somerville, E. M., Horwood, J. M., Lee, M. D., Kennett, G. A., and Clifton, P. G. (2007) 5-HT(2C)
receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-
fos immunoreactivity in mice, European Journal of Neuroscience 25, 3115-3124. 
[35] Tecott, L. H. (2007) Serotonin and the orchestration of energy balance, Cell Metabolism 6, 352-361.
[36] Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., and Julius, D.
(1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors, Nature 374, 542-546. 
[37] Vickers, S. P., Clifton, P. G., Dourish, C. T., and Tecott, L. H. (1999) Reduced satiating effect of d-
fenfluramine in serotonin 5-HT(2C) receptor mutant mice, Psychopharmacology (Berl) 143, 309-314. 
[38] Schellekens, H., Clarke, G., Jeffery, I. B., Dinan, T. G., and Cryan, J. F. (2012) Dynamic 5-HT2C receptor
editing in a mouse model of obesity, PLoS One 7, e32266. 
[39] Feijo, F. d. M., Bertoluci, M. C., and Reis, C. (2011) Serotonin and hypothalamic control of hunger: a
review, Rev. Assoc. Med. Bras 
 57, 74-77. 
[40] Wurtman, R. J., and Wurtman, J. J. (1988) Do carbohydrates affect food intake via neurotransmitter
activity?, Appetite 11, Supplement 1, 42-47. 
[41] Dalton, G. L., Lee, M. D., Kennett, G. A., Dourish, C. T., and Clifton, P. G. (2004) mCPP-induced
hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor 
subtypes, Neuropharmacology 46, 663-671. 
[42] Dalton, G. L., Lee, M. D., Kennett, G. A., Dourish, C. T., and Clifton, P. G. (2006) Serotonin 1B and 2C
receptor interactions in the modulation of feeding behaviour in the mouse, Psychopharmacology (Berl) 
185, 45-57. 
[43] Lam, D. D., and Heisler, L. K. (2007) Serotonin and energy balance: molecular mechanisms and
implications for type 2 diabetes, Expert Rev Mol Med 9, 1-24. 
[44] Jandacek, R. J. (2005) APD-356 (Arena), Current Opinion in Investigational Drugs 6, 1051-1056.
[45] Redman, L. M., and Ravussin, E. (2010) Lorcaserin for the treatment of obesity, Drugs Today (Barc) 46,
901-910.
[46] O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson,
C. M., and Shanahan, W. R. (2012) Randomized Placebo-Controlled Clinical Trial of Lorcaserin for
Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study, Obesity (Silver Spring).
ACS Paragon Plus Environment
ACS Chemical Neuroscience
24 
[47] Martin, C. K., Redman, L. M., Zhang, J., Sanchez, M., Anderson, C. M., Smith, S. R., and Ravussin, E. 
(2011) Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake 
without influencing energy expenditure, Journal of Clinical Endocrinology & Metabolism 96, 837-845. 
[48] Clemett, D. A., Punhani, T., Duxon, M. S., Blackburn, T. P., and Fone, K. C. (2000) Immunohistochemical
localisation of the 5-HT2C receptor protein in the rat CNS, Neuropharmacology 39, 123-132. 
[49] Leysen, J. E. (2004) 5-HT2 receptors, Curr Drug Targets CNS Neurol Disord 3, 11-26.
[50] Guan, X. M., Yu, H., Palyha, O. C., McKee, K. K., Feighner, S. D., Sirinathsinghji, D. J., Smith, R. G.,
Van der Ploeg, L. H., and Howard, A. D. (1997) Distribution of mRNA encoding the growth hormone 
secretagogue receptor in brain and peripheral tissues, Brain research 48, 23-29. 
[51] Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., and Elmquist, J. K. (2006) Expression of ghrelin
receptor mRNA in the rat and the mouse brain, The Journal of comparative neurology 494, 528-548. 
[52] Cowley, M. A., Smith, R. G., Diano, S., Tschop, M., Pronchuk, N., Grove, K. L., Strasburger, C. J.,
Bidlingmaier, M., Esterman, M., Heiman, M. L., Garcia-Segura, L. M., Nillni, E. A., Mendez, P., Low, 
M. J., Sotonyi, P., Friedman, J. M., Liu, H., Pinto, S., Colmers, W. F., Cone, R. D., and Horvath, T. L.
(2003) The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel
hypothalamic circuit regulating energy homeostasis, Neuron 37, 649-661.
[53] Brunetti, L., Recinella, L., Orlando, G., Michelotto, B., Di Nisio, C., and Vacca, M. (2002) Effects of
ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus, Eur J 
Pharmacol 454, 189-192. 
[54] Ghersi, M. S., Casas, S. M., Escudero, C., Carlini, V. P., Buteler, F., Cabrera, R. J., Schioth, H. B., and de
Barioglio, S. R. (2011) Ghrelin inhibited serotonin release from hippocampal slices, Peptides 32, 2367-
2371. 
[55] Hansson, C., Alvarez-Crespo, M., Taube, M., Skibicka, K. P., Schmidt, L., Karlsson-Lindahl, L.,
Egecioglu, E., Nissbrandt, H., and Dickson, S. L. (2014) Influence of ghrelin on the central 
serotonergic signaling system in mice, Neuropharmacology 79, 498-505. 
[56] Nonogaki, K., Ohashi-Nozue, K., and Oka, Y. (2006) A negative feedback system between brain serotonin
systems and plasma active ghrelin levels in mice, Biochem Biophys Res Commun 341, 703-707. 
[57] Currie, P. J., John, C. S., Nicholson, M. L., Chapman, C. D., and Loera, K. E. (2010) Hypothalamic
paraventricular 5-hydroxytryptamine inhibits the effects of ghrelin on eating and energy substrate 
utilization, Pharmacol Biochem Behav 97, 152-155. 
[58] Cabral, A., Fernandez, G., and Perello, M. (2013) Analysis of brain nuclei accessible to ghrelin present in
the cerebrospinal fluid, Neuroscience 253, 406-415. 
[59] Cabral, A., Valdivia, S., Fernandez, G., Reynaldo, M., and Perello, M. (2014) Divergent neuronal
circuitries underlying acute orexigenic effects of peripheral or central ghrelin: critical role of brain 
accessibility, Journal of neuroendocrinology 26, 542-554. 
[60] Berg, K. A., Clarke, W. P., Cunningham, K. A., and Spampinato, U. (2008) Fine-tuning serotonin2c
receptor function in the brain: molecular and functional implications, Neuropharmacology 55, 969-976. 
[61] Berg, K. A., Cropper, J. D., Niswender, C. M., Sanders-Bush, E., Emeson, R. B., and Clarke, W. P. (2001)
RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity, Br J 
Pharmacol 134, 386-392. 
[62] Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., and Emeson, R. B.
(1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing, Nature 387, 303-308. 
[63] Herrick-Davis, K., Grinde, E., and Niswender, C. M. (1999) Serotonin 5-HT2C receptor RNA editing alters
receptor basal activity: implications for serotonergic signal transduction, J Neurochem 73, 1711-1717. 
[64] Wang, Q., O'Brien, P. J., Chen, C. X., Cho, D. S., Murray, J. M., and Nishikura, K. (2000) Altered G
protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors, J 
Neurochem 74, 1290-1300. 
[65] Niswender, C. M., Copeland, S. C., Herrick-Davis, K., Emeson, R. B., and Sanders-Bush, E. (1999) RNA
editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity, Journal 
of Biological Chemistry 274, 9472-9478. 
[66] Olaghere da Silva, U. B., Morabito, M. V., Canal, C. E., Airey, D. C., Emeson, R. B., and Sanders-Bush, E.
(2010) Impact of RNA editing on functions of the serotonin 2C receptor in vivo, Front Neurosci 4, 26. 
[67] Werry, T. D., Loiacono, R., Sexton, P. M., and Christopoulos, A. (2008) RNA editing of the serotonin
5HT2C receptor and its effects on cell signalling, pharmacology and brain function, Pharmacol. 
Therapeut. 119, 7-23. 
[68] Kawahara, Y., Grimberg, A., Teegarden, S., Mombereau, C., Liu, S., Bale, T. L., Blendy, J. A., and K., N.
(2008) Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of 
fat mass, J. Neurosci. 28, 12834-12844. 
ACS Paragon Plus Environment
ACS Chemical Neuroscience
25 
[69] Kohno, D., Gao, H. Z., Muroya, S., Kikuyama, S., and Yada, T. (2003) Ghrelin directly interacts with 
neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and 
N-type channel-dependent mechanisms and cross-talk with leptin and orexin, Diabetes 52, 948-956.
[70] Suzuki, K., Simpson, K. A., Minnion, J. S., Shillito, J. C., and Bloom, S. R. (2010) The role of gut
hormones and the hypothalamus in appetite regulation, Endocr J 57, 359-372. 
[71] Simpson, K. A., Martin, N. M., and Bloom, S. R. (2009) Hypothalamic regulation of food intake and
clinical therapeutic applications, Arq Bras Endocrinol Metabol 53, 120-128. 
[72] Kanoski, S. E., Hayes, M. R., Greenwald, H. S., Fortin, S. M., Gianessi, C. A., Gilbert, J. R., and Grill, H.
J. (2011) Hippocampal Leptin Signaling Reduces Food Intake and Modulates Food-Related Memory
Processing, Neuropsychopharmacology.
[73] Bubar, M. J., and Cunningham, K. A. (2007) Distribution of serotonin 5-HT2C receptors in the ventral
tegmental area, Neuroscience 146, 286-297. 
[74] Pompeiano, M., Palacios, J. M., and Mengod, G. (1994) Distribution of the serotonin 5-HT2 receptor
family mRNAs: comparison between 5-HT2A and 5-HT2C receptors, Brain Res Mol Brain Res 23, 
163-178.
[75] Bonn, M., Schmitt, A., and Asan, E. (2012) Double and triple in situ hybridization for coexpression studies:
combined fluorescent and chromogenic detection of neuropeptide Y (NPY) and serotonin receptor 
subtype mRNAs expressed at different abundance levels, Histochemistry and cell biology 137, 11-24. 
[76] Bonn, M., Schmitt, A., Lesch, K. P., Van Bockstaele, E. J., and Asan, E. (2013) Serotonergic innervation
and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral 
amygdaloid nuclei, Brain structure & function 218, 421-435. 
[77] Diano, S. (2008) Ghrelin's role in feeding behavior and memory performance, Appetite 51, 363-363.
[78] Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N.,
Jaeger, L. B., Banks, W. A., Morley, J. E., Pinto, S., Sherwin, R. S., Xu, L., Yamada, K. A., Sleeman, 
M. W., Tschop, M. H., and Horvath, T. L. (2006) Ghrelin controls hippocampal spine synapse density
and memory performance, Nature neuroscience 9, 381-388.
[79] Schwartz, G. J. (2000) The role of gastrointestinal vagal afferents in the control of food intake: current
prospects, Nutrition 16, 866-873. 
[80] Benoit, S., Schwartz, M., Baskin, D., Woods, S. C., and Seeley, R. J. (2000) CNS melanocortin system
involvement in the regulation of food intake, Horm Behav 37, 299-305. 
[81] Branchek, T. A., and Gershon, M. D. (1989) Time course of expression of neuropeptide Y, calcitonin gene-
related peptide, and NADPH diaphorase activity in neurons of the developing murine bowel and the 
appearance of 5-hydroxytryptamine in mucosal enterochromaffin cells, J Comp Neurol 285, 262-273. 
[82] McGirr, R., McFarland, M. S., McTavish, J., Luyt, L. G., and Dhanvantari, S. (2011) Design and
characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 
1a, Regulatory peptides 172, 69-76. 
[83] Finger, B. C., Schellekens, H., Dinan, T. G., and Cryan, J. F. (2011) Is there altered sensitivity to ghrelin-
receptor ligands in leptin-deficient mice?: importance of satiety state and time of day, 
Psychopharmacology (Berl) 216, 421-429. 
[84] Diz-Chaves, Y. (2011) Ghrelin, appetite regulation, and food reward: interaction with chronic stress, Int J
Pept 2011, 898450. 
[85] Chuang, J. C., Perello, M., Sakata, I., Osborne-Lawrence, S., Savitt, J. M., Lutter, M., and Zigman, J. M.
(2011) Ghrelin mediates stress-induced food-reward behavior in mice, The Journal of clinical 
investigation 121, 2684-2692. 
[86] Schellekens, H., Dinan, T. G., and Cryan, J. F. (2013) Ghrelin at the interface of obesity and reward,
Vitamins and hormones 91, 285-323. 
[87] Schellekens, H., Finger, B. C., Dinan, T. G., and Cryan, J. F. (2012) Ghrelin signalling and obesity: At the
interface of stress, mood and food reward, Pharmacol Ther 135, 316-326. 
[88] Skibicka, K. P., Hansson, C., Egecioglu, E., and Dickson, S. L. (2012) Role of ghrelin in food reward:
impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor 
gene expression, Addict Biol 17, 95-107. 
[89] Skibicka, K. P., and Dickson, S. L. (2011) Ghrelin and food reward: the story of potential underlying
substrates, Peptides 32, 2265-2273. 
[90] Egecioglu, E., Skibicka, K. P., Hansson, C., Alvarez-Crespo, M., Friberg, P. A., Jerlhag, E., Engel, J. A.,
and Dickson, S. L. (2011) Hedonic and incentive signals for body weight control, Rev Endocr Metab 
Disord 12, 141-151. 
[91] Dickson, S. L., Egecioglu, E., Landgren, S., Skibicka, K. P., Engel, J. A., and Jerlhag, E. (2011) The role of
the central ghrelin system in reward from food and chemical drugs, Molecular and cellular 
endocrinology 340, 80-87. 
ACS Paragon Plus Environment
ACS Chemical Neuroscience
26 
[92] Perello, M., and Zigman, J. M. (2012) The role of ghrelin in reward-based eating, Biol Psychiatry 72, 347-
353. 
[93] Alex, K. D., and Pehek, E. A. (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine
neurotransmission, Pharmacol Ther 113, 296-320. 
[94] Higgins, G. A., and Fletcher, P. J. (2003) Serotonin and drug reward: focus on 5-HT2C receptors, Eur J
Pharmacol 480, 151-162. 
[95] Liu, S., and Borgland, S. L. (2015) Regulation of the mesolimbic dopamine circuit by feeding peptides,
Neuroscience 289C, 19-42. 
[96] Di Matteo, V., Cacchio, M., Di Giulio, C., and Esposito, E. (2002) Role of serotonin(2C) receptors in the
control of brain dopaminergic function, Pharmacol Biochem Behav 71, 727-734. 
[97] Skibicka, K. P., Hansson, C., Alvarez-Crespo, M., Friberg, P. A., and Dickson, S. L. (2011) Ghrelin
directly targets the ventral tegmental area to increase food motivation, Neuroscience. 
[98] Schwartz, M. W., Woods, S. C., Porte, D., Jr., Seeley, R. J., and Baskin, D. G. (2000) Central nervous
system control of food intake, Nature 404, 661-671. 
[99] Schellekens, H., McNamara, O., Dinan, T. G., McCarthy, J. V., McGlacken, G. P., and Cryan, J. F. (2013)
Semagacestat, a gamma-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) 
receptor, J Pharm Pharmacol 65, 528-538. 
[100] Morabito, M. V., Abbas, A. I., Hood, J. L., Kesterson, R. A., Jacobs, M. M., Kump, D. S., Hachey, D. L.,
Roth, B. L., and Emeson, R. B. (2010) Mice with altered serotonin 2C receptor RNA editing display 
characteristics of Prader-Willi syndrome, Neurobiol Dis 39, 169-180. 
[101] Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K.,
Tomancak, P., and Cardona, A. (2012) Fiji: an open-source platform for biological-image analysis, Nat 
Methods 9, 676-682. 
ACS Paragon Plus Environment
ACS Chemical Neuroscience
27 
FIGURE LEGENDS 
Figure 1 FRET between the 5-HT2C and GHS-R1a receptor. Hek293A cells stably expressing 
the 5-HT2C receptor as an eGFP fusion protein or the partially edited 5-HT2C isoform, 5-HT2C-
VSV-eGFP, were transiently transduced with lentiviral vectors expressing control-TagRFP or 
GHS-R1a-TagRFP. Cells were analysed 72 hrs post transduction using LSRii flow cytometry. Dot 
plots are representative of three independent experiments. Percentages indicate levels of 
TagRFP expression (TagRFP vs eGFP plots) or FRET levels as a percentage of TagRFP 
expression (FRET vs eGFP plots). 
Figure 2 Co-expression of the 5-HT2C receptor attenuates GHS-R1a-mediated intracellular 
calcium mobilization. The ligand-mediated intracellular calcium increase in Hek293A cells 
stably expressing the GHS-R1a receptor only (solid bars) was reduced when co-expressing the 
5-HT2C receptor (striated bars), following exposure to different concentrations of ghrelin (A) or
different concentrations of the synthetic agonist, MK0677 (B). Intracellular calcium mobilization 
was depicted in relative fluorescence units (RFU) as a percentage of maximal calcium increase 
as elicited by the control (3.3 % FBS). Graph represents the mean ± SEM of triplicate samples. 
Statistical significance of ligand-mediated calcium mobilization obtained in double expressing 
cells compared to cells solely expressing the GHS-R1a receptor is denoted as * indicating p<0.05, 
** indicating p<0.01 or *** indicating p<0.001. 
Figure 3 Co-expression of the 5-HT2C receptor and the GHS-R1a receptor does not 
influence cAMP signalling. The dopamine D1 receptor agonist, 6,7-ADTN hydrobromide (0.5 
nM), induces an increase in cAMP in human embryonic cells transiently expressing the D1 
receptor following lentiviral transduction (lvDRD1-tagRFP) but not in cells stably expressing 
the 5-HT2C receptor (A) or the GHS-R1a receptor (B). Co-expression of the GHS-R1a receptor, 
following lentiviral transduction (lvGHS-R1a-EGFP) in cells stably expressing the 5-HT2C 
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receptor does not induce intracellular cAMP production (C). Neither does lentiviral co-
expression of 5-HT2C receptor (lv5HT2C-EGFP) in cells stably expressing the GHS-R1a receptor 
(D). Intracellular basal (nonstimulated) cAMP level was used for comparison (black bars). The 
data is depicted as the mean ± SEM with each concentration point performed in triplicate. 
Statistical significance is denoted as a= p<0.001 compared to vehicle (-) and b= p<0.001 
compared to 5-HT (A) or ghrelin (Ghrl) (B), respectively. 
Figure 4 Co-localization of the 5-HT2C receptor and ghrelin-fluorescein staining in rat 
hippocampal and hypothalamic neurons. Primary cultured hypothalamic (top panel) and 
hippocampal (bottom panel) cells were shown to express the 5-HT2C receptor, indicated in red, 
and to also bind fluorescein-ghrelin, indicated in green. Overlapping expression is indicated in 
yellow. Nuclear stain by bisbenzimide is indicated in blue. Data is representative of three 
independent staining experiments of primary cultured hippocampal neurons (left and right) 
from day 17 rat embryos (E17). 
Figure 5 Specific 5-HT2C receptor antagonism potentiates ghrelin’s orexigenic effect 
in vivo. Cumulative food intake (A) and food intake at time-points 1, 8 and 24 hour (B, C, D) 
are depicted for ad libitum fed male C57Bl/6 mice following intraperitoneal administration 
of the brain-penetrant 5-HT2C receptor antagonist SB242084 (2 mg/kg) or vehicle 1 
(saline+ 1% DMSO) followed by ghrelin (200 nmol/kg) or vehicle 2 (saline). Results are 
depicted ± SEM. Statistical significant differences compared to Vehicle-Vehicle (A) and 
between all groups (B, C, D) at each time point are depicted as * indicating p<0.05, ** 
indicating p<0.01 or *** indicating p<0.001, n=8 per group. 
Figure 6 Specific 5-HT2C receptor agonism attenuates ghrelin’s orexigenic effect in 
vivo. Cumulative food intake (A) and food intake at time-points 20 min, 1 and 8 hour (B, C, 
D) are depicted for ad libitum fed male C57Bl/6 mice following subcutaneous
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administration of the 5-HT2C specific agonist lorcaserin (3 mg/kg) or vehicle 1 (saline; 1% 
DMSO) followed by intraperitoneal ghrelin (200 nmol/kg) or vehicle 2 (saline). Results are 
depicted ± SEM. Statistical significant differences compared to Vehicle-Vehicle (A) and 
between all groups (B, C, D) at each time point are depicted as * indicating p<0.05, ** 
indicating p<0.01 or *** indicating p<0.001, n=7-10 per group. 
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